These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16989997)

  • 1. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.
    Lacroix-Triki M; Mathoulin-Pelissier S; Ghnassia JP; Macgrogan G; Vincent-Salomon A; Brouste V; Mathieu MC; Roger P; Bibeau F; Jacquemier J; Penault-Llorca F; Arnould L
    Eur J Cancer; 2006 Nov; 42(17):2946-53. PubMed ID: 16989997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reproducibility of Her-2/neu overexpression with HERCEP test in invasive ductal breast cancer].
    Rodríguez Moguel L; Vega Ramos B
    Ginecol Obstet Mex; 2002 Dec; 70():601-6. PubMed ID: 12661333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest.
    Hsu CY; Ho DM; Yang CF; Lai CR; Yu IT; Chiang H
    Am J Clin Pathol; 2002 Nov; 118(5):693-8. PubMed ID: 12428788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
    Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.
    Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
    Am J Clin Pathol; 2000 Feb; 113(2):251-8. PubMed ID: 10664627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry.
    Al Haddabi I; Qureshi A; Saparamadu A; Al Hamdani A; Al Riyami M; Ganguly S
    Indian J Pathol Microbiol; 2014; 57(2):201-4. PubMed ID: 24943750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Borderline HER-2 breast cancer cases: histochemical versus real-time PCR analysis and impact of different cut-off values.
    Monego G; Arena V; Maggiano N; Costarelli L; Crescenzi A; Zelano G; Amini M; Capelli A; Carbone A
    Scand J Clin Lab Invest; 2007; 67(4):402-12. PubMed ID: 17558895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
    Sharif MA; Mamoon N; Mushtaq S; Khadim MT
    J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-phase study model for the standardization of HER2 immunohistochemical assay on invasive ductal carcinoma of the breast.
    Sampatanukul P; Chaiwun B; Wongwaisayawan S; Suwanagool P; Vinyuvat S; Karalak A; Praditphol N; Paueksakon P; Ruangvejvorachai P; Field AS; Wannakrairot P
    J Med Assoc Thai; 2005 Nov; 88(11):1680-8. PubMed ID: 16471119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
    Shin SJ; Hyjek E; Early E; Knowles DM
    Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
    Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
    Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
    Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
    Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.
    Rhodes A; Jasani B; Anderson E; Dodson AR; Balaton AJ
    Am J Clin Pathol; 2002 Sep; 118(3):408-17. PubMed ID: 12219783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.